LRG1 has also been evaluated in plasma alongside TTR and CA19-9, where this panel exceeded the accuracy of CA19-9 alone by over 10% in its ability to discriminate PDAC from benign controls and other cancers (59). This evidence concerns the gene TTR and cancer.